Evotec SE (EVO) Cash Flow Statement

NASDAQ: EVOOperating cash, capex, free cash flow and buybacks.

Where EVO’s cash came from and went, 2025

December 31, 2025 · euros
Cash from operations
−€9.1M
−149.8% vs 2024
Capital expenditures
€69.7M
9.2% of revenue
Free cash flow
−€78.7M
−10.4% margin
Returned to shareholders
€1.5M
Change in cash
€148.3M
cash at year-end €418.3M
Investments (net): €32.0MInvestments (net)€32.0MAcquisitions & other: €197.6MAcquisitions & other€197.6MCurrency & other: €28.5MCurrency & other€28.5MCapital expenditures: €69.7MCapital expenditures€69.7M · 27%Debt repayment: €29.4MDebt repayment€29.4M · 11%Cash used in operations: €9.1MCash used in operations€9.1M · 4%Added to cash: €148.3MAdded to cash€148.3M · 57%Share buybacks: €1.5MShare buybacks€1.5M · 1%€258.0M
Cash from operations
−€9.1M
Capital expenditures
−€69.7M
Investments (net)
+€32.0M
Acquisitions & other
+€197.6M
Share buybacks (net)
−€1.5M
Net borrowing (repayment)
−€29.4M
Currency & other
+€28.5M
Change in cash
€148.3M

Drawn to scale: where the cash came from and how it was used. Hover for values.

EVO operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

EVO cash flow trends, 2015–2025

Evotec SE cash flow trends
MetricTrendThenLatestChange
Operating cash flow€15.7M2015−€9.1M2025—
Capital expenditures€11.5M2015€69.7M2025+22.2%/yr
Free cash flow€4.2M2015−€78.7M2025—
Free cash flow margin3.3%2015−10.4%2025−13.7 pts
Operating cash flow / net income0.9520150.572021−0.38
Stock-based compensation€4.0M2015€3.8M2025−0.6%/yr
Dividends paid€551,0002015€02025−100.0%
Share buybacks (net)€02015€1.5M2025—
Capex / revenue9.0%20159.2%2025+0.2 pts

Change is the average annual growth (CAGR) or the difference between the first and latest year.

EVO cash flow by activity

OperatingInvestingFinancingChange in cash

EVO net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

EVO cash flow statement in euros

Evotec SE annual cash flow statement
2025202420222021202020192018201720162015
Operating activities
Net income−€99.4M−€196.1M−€175.7M€215.5M€6.3M€37.3M€84.1M€24.0M€26.8M€16.5M
Depreciation & amortization€95.5M€101.6M€83.2M€67.6M€56.1M€48.8M€31.3M€20.8M€11.9M€11.9M
Stock-based compensation€3.8M€5.0M€9.9M€7.8M€5.3M€3.6M€4.2M€2.9M€4.0M€4.0M
Change in working capital−€58.4M−€68.2M€105.3M−€2.3M−€36.9M−€68.9M€71.9M−€35.7M€19.2M€3.5M
Other non-cash items€49.4M€175.9M€183.1M−€166.4M€14.0M€21.3M−€35.3M−€1.2M€5.4M−€20.3M
Cash from operating activities−€9.1M€18.2M€205.8M€122.2M€44.7M€42.2M€156.2M€10.8M€67.4M€15.7M
Investing activities
Capital expenditures−€69.7M−€132.2M−€181.4M−€118.9M−€99.1M−€31.9M−€27.9M−€17.6M−€10.1M−€11.5M
Investments (net)€32.0M−€71.2M−€415.8M−€117.1M−€38.8M−€14.3M−€27.2M−€4.1M——
Acquisitions & other investing€197.6M€132.2M€184.4M−€7.8M−€17.2M−€40.4M€15.9M−€247.4M€4.2M−€11.9M
Cash from investing activities€159.9M−€71.2M−€412.8M−€243.9M−€155.1M−€86.6M−€39.1M−€269.0M−€6.0M−€23.4M
Financing activities
Dividends paid€0€0€0€0———−€1.7M−€2.0M−€551,000
Share repurchases & issuance (net)−€1.5M€0——————−€17.6M€2.0M
Net borrowing (repayment)−€29.4M−€152.1M−€53.1M−€5.9M−€5.2M€209.4M−€79.3M€148.4M——
Shares issued€0€0€355,000€403.1M€250.0M€1.9M€0€0€0€0
Other financing€32,046−€9.3M−€5.4M€1.2M€1.6M€0€1.6M€94.1M−€78,177€1.0M
Cash from financing activities−€30.9M−€161.4M−€58.1M€398.4M€246.4M€211.3M−€77.8M€240.7M−€19.7M€2.5M
Summary
Net change in cash€148.3M−€204.5M−€284.2M€276.7M€145.5M€168.0M€42.0M−€16.9M€39.4M−€4.2M
Cash at end of period€418.3M€306.4M€415.2M€699.3M€422.6M€277.0M€109.1M€67.0M€83.9M€44.5M
Free cash flow−€78.7M−€114.0M€24.5M€3.3M−€54.4M€10.3M€128.4M−€6.8M€57.2M€4.2M
Free cash flow margin−10.4%−14.3%3.3%0.5%−10.9%2.3%34.2%−2.6%34.8%3.3%
Capex / revenue9.2%16.6%24.1%19.2%19.8%7.1%7.4%6.8%6.2%9.0%
Operating cash flow / net income———0.577.151.131.860.452.510.95

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported; data from EODHD.

EVO cash generation

In fiscal 2025 (ended December 31, 2025), Evotec generated -€9.1 million of cash from operations (down 149.8%) and spent €69.7 million on capital expenditures, leaving free cash flow of -€78.7 million, −10.4% of revenue. It returned €1.5 million to shareholders through dividends (€0) and net share buybacks (€1.5 million). Cash and equivalents rose by €148.3 million over the year.

Related: EVO income statement, EVO balance sheet. See the EVO stock overview for the latest quote and news.

EVO cash flow FAQ

What is Evotec's free cash flow?

Evotec's free cash flow was -€78.7 million in fiscal 2025: -€9.1 million of operating cash flow minus €69.7 million of capital expenditures It was -€114.0 million a year earlier..

How much cash does Evotec generate from operations?

Evotec generated -€9.1 million of cash from operating activities in fiscal 2025.

How much does Evotec spend on capital expenditures?

Evotec spent €69.7 million on capital expenditures in fiscal 2025, 9.2% of revenue, compared with €132.2 million the year before.

How much stock does Evotec buy back?

Evotec spent €1.5 million on net share repurchases in fiscal 2025.

Drug Manufacturers - Specialty & Generic: cash flow